ASHLIN CHARBONEAU: Open Payments
NPI 1114571536 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$976 in 32 payments from 13 companies in 2025. Trend: 2023 $2,414 · 2024 $2,891 · 2025 $976
Food & beverage: $976
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $236 |
| Novartis Pharmaceuticals Corporation | 5 | $153 |
| GlaxoSmithKline, LLC. | 4 | $100 |
| Incyte Corporation | 3 | $79 |
| AstraZeneca Pharmaceuticals LP | 2 | $66 |
| Astellas Pharma US Inc | 2 | $63 |
| Syndax Pharmaceuticals, Inc. | 2 | $62 |
| Adaptive Biotechnologies Corporation | 3 | $58 |
| Lilly USA, LLC | 2 | $53 |
| TAIHO ONCOLOGY, INC. | 1 | $35 |
Products named: SCEMBLIX, IMBRUVICA, OJJAARA, JAKAFI, VENCLEXTA, CALQUENCE, clonoSEQ, JAYPIRCA.
Industry payments across TX — which companies pay providers there.
